- Home
- DT vs SNN Comparison
DT vs SNN Comparison
Compare DT & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DT
- SNN
- Stock Information
- Founded
- DT 2005
- SNN 1856
- Country
- DT United States
- SNN United Kingdom
- Employees
- DT N/A
- SNN N/A
- Industry
- DT Computer Software: Prepackaged Software
- SNN Industrial Specialties
- Sector
- DT Technology
- SNN Health Care
- Exchange
- DT Nasdaq
- SNN Nasdaq
- Market Cap
- DT 15.2B
- SNN 15.2B
- IPO Year
- DT 2019
- SNN 1999
- Fundamental
- Price
- DT $46.75
- SNN $32.78
- Analyst Decision
- DT Buy
- SNN Hold
- Analyst Count
- DT 22
- SNN 4
- Target Price
- DT $62.14
- SNN $32.83
- AVG Volume (30 Days)
- DT 3.8M
- SNN 613.9K
- Earning Date
- DT 11-05-2025
- SNN 10-30-2025
- Dividend Yield
- DT N/A
- SNN 2.24%
- EPS Growth
- DT 208.33
- SNN 59.91
- EPS
- DT 1.66
- SNN 0.56
- Revenue
- DT $1,852,532,000.00
- SNN $5,944,000,000.00
- Revenue This Year
- DT $20.09
- SNN $7.85
- Revenue Next Year
- DT $14.56
- SNN $5.43
- P/E Ratio
- DT $28.14
- SNN $28.37
- Revenue Growth
- DT 18.50
- SNN 5.35
- 52 Week Low
- DT $39.30
- SNN $23.69
- 52 Week High
- DT $63.00
- SNN $38.79
- Technical
- Relative Strength Index (RSI)
- DT 41.04
- SNN 32.54
- Support Level
- DT $45.84
- SNN $33.05
- Resistance Level
- DT $47.60
- SNN $33.66
- Average True Range (ATR)
- DT 1.63
- SNN 0.49
- MACD
- DT -0.27
- SNN -0.34
- Stochastic Oscillator
- DT 26.22
- SNN 17.80
About DT Dynatrace Inc.
Dynatrace is a software-as-a-service company that enables customers to monitor and analyze their information technology infrastructure, from servers to applications and Python scripts. Dynatrace's unified platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to optimize their business for service-level objectives and ensure uptime.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.